TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9397100

Group type: EXPERIMENTAL
Intervention: Scoring system for predicting vaginal birth after cesarean delivery
Number of subjects: 5022

Group type: COMPARATOR
Intervention: Control group (score testing)
Number of subjects: 5022
Study: 8188494

Group type: EXPERIMENTAL
Intervention: Intervention group with employee steering committees selecting health education and environmental change activities.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 26
Study: 3668801

Group type: EXPERIMENTAL
Intervention: oral solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: intravenous infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: oral capsules
Number of subjects: 12
Study: 29306880

Group type: EXPERIMENTAL
Intervention: Smoke-free law compliance measures (systematic objective observations)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Knowledge and opinions regarding the smoke-free law
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Air quality testing (PM 2.5 levels)
Number of subjects: 222
Study: 27647671

Group type: EXPERIMENTAL
Intervention: Open-label lithium
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 42
Study: 25544247

Group type: EXPERIMENTAL
Intervention: Sufentanil 15 μg sublingual tablet (SL) administered using the SSTS system
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sufentanil 15 μg sublingual tablet (SL) administered using the SSTS system (40 consecutive doses)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of sufentanil
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sufentanil buccal (BU) administration
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sufentanil oral (PO) administration
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sufentanil sublingual (SL) administration
Number of subjects: 38
Study: 22855038

Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony capsule (TGPC), 600 mg per time, three times daily for three months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Compound glycyrrhizin tablet, 50 mg per time, three times daily for three months
Number of subjects: 86
Study: 20798432

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stopping antiplatelet agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional approach of stopping medications up to two weeks before surgery
Number of subjects: 0
Study: 18718769

Group type: EXPERIMENTAL
Intervention: Reverse foam sclerotherapy with sapheno-femoral junction (SFJ) ligation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard stripping with SFJ ligation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Invagination stripping with SFJ ligation
Number of subjects: 90
Study: 16298920

Group type: EXPERIMENTAL
Intervention: Latency of 500 ms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Higher latency (greater than 300 ms)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Different latencies
Number of subjects: 5
Study: 12463311

Group type: EXPERIMENTAL
Intervention: Plant stanol ester margarine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 81
Study: 10514159

Group type: EXPERIMENTAL
Intervention: Very low intensity coumarin (international normalised ratio 1.1-1.6)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Standard intensity coumarin (international normalised ratio 2.5-3.5)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Low anticoagulation
Number of subjects: 729

Group type: COMPARATOR
Intervention: Aspirin (150 mg/day)
Number of subjects: 729
Study: 8719595

Group type: EXPERIMENTAL
Intervention: AgNOR staining
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: DNA cytofluorometry
Number of subjects: 73
Study: 2201721

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg or higher
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zopiclone 11.25 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zopiclone 15 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zopiclone 3.5 mg and 7.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zopiclone up to 11.25 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zopiclone higher doses when well tolerated
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 84947

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 0
Study: 30912259

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 909

Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 909
Study: 29020150

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1.0 g, intravenously, once daily for 10 days)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Benzathine Penicillin G (2.4 million units, intramuscularly, once weekly for 2 weeks)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Benzathine Penicillin G
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ceftriaxone or BPG
Number of subjects: 301
Study: 25695770

Group type: EXPERIMENTAL
Intervention: Resistance training (n = 19)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Balance training (n = 14)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 53
Study: 22904115

Group type: EXPERIMENTAL
Intervention: Active exercise program (experimental group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Relaxation only (control group)
Number of subjects: 20
Study: 19095403

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing
Number of subjects: 139

Group type: COMPARATOR
Intervention: Clinical algorithm (control)
Number of subjects: 139
Study: 19585767

Group type: EXPERIMENTAL
Intervention: Combat medic training
Number of subjects: 3792
Study: 16990966

Group type: EXPERIMENTAL
Intervention: VBM laryngeal tube (LT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 40
Study: 15208051

Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg weekly
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mifepristone 10 mg planned postcoitally
Number of subjects: 40
Study: 11122028

Group type: EXPERIMENTAL
Intervention: Real-time teledermatology
Number of subjects: 96

Group type: COMPARATOR
Intervention: Store-and-forward teledermatology
Number of subjects: 96
Study: 9272610

Group type: EXPERIMENTAL
Intervention: Therapies that lower glucose levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8441426

Group type: EXPERIMENTAL
Intervention: 20 ft3 (0.57 m3) of outdoor air per minute per person
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: 50 ft3 (1.4 m3) of outdoor air per minute per person
Number of subjects: 1546
Study: 3533776

Group type: EXPERIMENTAL
Intervention: Milch's technique
Number of subjects: 111

Group type: COMPARATOR
Intervention: Kocher's technique
Number of subjects: 111
Study: 30947737

Group type: EXPERIMENTAL
Intervention: Intervention practices received £1500, a support manual, and four meetings to develop local solutions.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Practice A: a stacked telephone system and promoting community transport.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Practice B: signposting to community transport, appointment flexibility, mobility scooter charging point, and promoting the role of receptionists.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Practice C: local taxi firm partnership and training receptionists.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 34
Study: 29736007

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 63
Study: 26943612

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) volume above the median
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) density above the median
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Seminal vesicle involvement
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 201
Study: 24345080

Group type: EXPERIMENTAL
Intervention: Haptoglobin phenotype (1-1, 2-1, 2-2)
Number of subjects: 2184
Study: 22784348

Group type: EXPERIMENTAL
Intervention: Ageratina pichinchensis extract (0.76%)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ageratina pichinchensis extract (1.52%)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 2% ketoconazole
Number of subjects: 160
Study: 20124509

Group type: EXPERIMENTAL
Intervention: Bortezomib, lenalidomide, and dexamethasone maintenance for 3 years
Number of subjects: 480

Group type: COMPARATOR
Intervention: Bortezomib, thalidomide, and dexamethasone in year 1 and thalidomide/dexamethasone in years 2 and 3
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: GEP-defined high-risk designation
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Mathematical modeling of CRD in low-risk myeloma
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: CCND1 without CD20 myeloma
Number of subjects: 480
Study: 16729880

Group type: EXPERIMENTAL
Intervention: Joint mobilisation twice a week for four weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard exercise programme
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Joint mobilisation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Joint mobilisation and standard exercise programme
Number of subjects: 90
Study: 15499515

Group type: EXPERIMENTAL
Intervention: Participation in smoking cessation counselling
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Stage of change
Number of subjects: 642
Study: 11737044

Group type: EXPERIMENTAL
Intervention: Hot, humid air (HHA: 37 degrees C, > 95% relative humidity)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Room air (25 degrees C, 30% RH)
Number of subjects: 20
Study: 9159724

Group type: EXPERIMENTAL
Intervention: Behavioral treatment for 10 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonspecific psychological treatment (control) for 10 weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonspecific psychological treatment (control)
Number of subjects: 29
Study: 8292465

Group type: EXPERIMENTAL
Intervention: 5 mg quinapril
Number of subjects: 2242

Group type: EXPERIMENTAL
Intervention: 10 mg quinapril
Number of subjects: 2242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2242
Study: 3541830

Group type: EXPERIMENTAL
Intervention: Imipramine (up to 5 mg/kg/d)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Imipramine plus desipramine (plasma level study)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Depressive hallucinations during the episode
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Weight-corrected imipramine dosage
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 53
Study: 31910896

Group type: EXPERIMENTAL
Intervention: Tamalakyadi decoction (TMD12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Freeze-dried formulation of Tamalakyadi decoction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihistamine loratadine (control)
Number of subjects: 0
Study: 29417614

Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 1997
Study: 27977600

Group type: EXPERIMENTAL
Intervention: Sufentanil 2.0 μg/kg + dexmedetomidine 2.0 μg/kg (group S2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.15 mg/kg + dexmedetomidine 2.0 μg/kg (group N2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.15 mg/kg + dexmedetomidine 1.5 μg/kg (group N1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 2.0 μg/kg + dexmedetomidine 1.5 μg/kg (group S1)
Number of subjects: 80
Study: 23624699

Group type: EXPERIMENTAL
Intervention: Topical APF gel (1.23 % F, pH 3.5, for 4 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er, Cr:YSGG laser (P:0.25 W, E:12.5 mJ, RR:20 Hz, PD:140 μs, 11 % air, without water, for 10 s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoride + laser group (F + L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 60
Study: 22048714

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: F/V diet
Number of subjects: 381
Study: 20075768

Group type: EXPERIMENTAL
Intervention: Surgery for degenerative spondylolisthesis (DS)
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Surgery for spinal stenosis (SPS)
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Nonoperative treatment for both DS and SPS
Number of subjects: 1235
Study: 17942179

Group type: COMPARATOR
Intervention: Cognitive task requiring little attention (forward counting)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Highly demanding cognitive task (arithmetic manipulation)
Number of subjects: 64
Study: 15533612

Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated omega3 fatty acids (LCn3) from oil-rich fish
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary advice to eat more oil-rich fish or take LCn3 supplements
Number of subjects: 0
Study: 12812661

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of immunotoxin (IT) once a week for 8 weeks and then once every month for 8 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Calmette‐Guerin vaccine (BCG) once a week for 8 weeks and then once every month for 8 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Mitomycin (MMC) once a week for 8 weeks and then once every month for 8 months
Number of subjects: 128
Study: 11061615

Group type: EXPERIMENTAL
Intervention: BIP + RT (bleomycin 30 units/24‐hour infusion, ifosfamide 5 g/m2/24 hours, cisplatin 50 mg/m2 followed by pelvic radiotherapy)
Number of subjects: 172

Group type: COMPARATOR
Intervention: RT (pelvic radiotherapy alone)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: BIP + RT
Number of subjects: 172

Group type: COMPARATOR
Intervention: RT
Number of subjects: 172
Study: 9293972

Group type: EXPERIMENTAL
Intervention: Captopril (mean dose 46/69 mg/day after 7 days/4 weeks)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 208
Study: 8297841

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 71
Study: 3550679

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31997543

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric intervention programme (CGIP) - Class-styled (CS) sessions
Number of subjects: 526

Group type: COMPARATOR
Intervention: Comprehensive geriatric intervention programme (CGIP) - Home-based (HB) programme
Number of subjects: 526
Study: 29656937

Group type: EXPERIMENTAL
Intervention: MynxGrip®
Number of subjects: 208

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 208
Study: 26963569

Group type: EXPERIMENTAL
Intervention: Individually tailored physical training and activity for 3 months
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 322
Study: 23768518

Group type: EXPERIMENTAL
Intervention: Mega-dose vitamin A supplementation (MVAS) of 60 mg administered at diagnosis and again after 1 month.
Number of subjects: 262
Study: 23322206

Group type: COMPARATOR
Intervention: FLO (infusional 5-FU, leucovorin, and oxaliplatin)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: FLOT (infusional 5-FU, leucovorin, oxaliplatin, and docetaxel 50 mg/m²)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both FLO and FLOT
Number of subjects: 44
Study: 20626444

Group type: EXPERIMENTAL
Intervention: Topical application of a gel containing allium cepa, allantoin, and pentaglycan twice a day for 24 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: No topical treatments
Number of subjects: 30
Study: 18955038

Group type: EXPERIMENTAL
Intervention: Spatial attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Object-based attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral cueing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central cueing
Number of subjects: 0
Study: 16508264

Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid gel for 1 min
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid gel for 4 min
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluoridated salt
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluoride gel
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Gingival bleeding
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: DeltaQ
Number of subjects: 44
Study: 12953945

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v in combination with metronidazole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo in combination with metronidazole
Number of subjects: 20
Study: 14564593

Group type: EXPERIMENTAL
Intervention: Group 1: low loading dose and high demand bolus
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Group 2: high loading dose and demand bolus
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Group 3: high loading dose and low demand bolus
Number of subjects: 21
Study: 8961467

Group type: EXPERIMENTAL
Intervention: Stochastic model for binary data assessment
Number of subjects: 0
Study: 1387484

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 2963

Group type: EXPERIMENTAL
Intervention: Active Control
Number of subjects: 2963

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2963
Study: 6365104

Group type: EXPERIMENTAL
Intervention: 2.5 mg tulobuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2.5 mg fenoterol
Number of subjects: 0
Study: 30879366

Group type: EXPERIMENTAL
Intervention: Continuous probiotics (1 capsule daily for 6 weeks after 7 days of clindamycin 2% vaginal cream)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Interrupted probiotics (1 capsule twice a week for 6 weeks after 7 days of clindamycin 2% vaginal cream)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Continuous probiotics
Number of subjects: 273

Group type: COMPARATOR
Intervention: Interrupted probiotics
Number of subjects: 273
Study: 29648571

Group type: EXPERIMENTAL
Intervention: Dads And Daughters Exercising and Empowered (DADEE) program
Number of subjects: 268

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 268
Study: 29117153

Group type: EXPERIMENTAL
Intervention: Optimized constant-modulus (CM) waveforms (arbitrary-phase and QPSK) designed through a customized Gaussian randomization method.
Number of subjects: 0

Group type: COMPARATOR
Intervention: LFM waveforms
Number of subjects: 0
Study: 26158415

Group type: EXPERIMENTAL
Intervention: Rubber dam isolation (RD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cotton rolls/retraction cord isolation (CR/RC)
Number of subjects: 30
Study: 23797529

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adverse events (graft rejection reactions and infections)
Number of subjects: 30
Study: 21704889

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized house dust mite extract
Number of subjects: 134
Study: 19770374

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (cisplatin and fluorouracil)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 802
Study: 16532765

Group type: EXPERIMENTAL
Intervention: Controller for skeletal muscle relaxation using mivacurium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anesthesiologist's manual control
Number of subjects: 0
Study: 15307543

Group type: EXPERIMENTAL
Intervention: Molecular Adsorbent Recirculating System (MARS) for 3 consecutive days; continued if bilirubin > 6 mg/dl
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional therapy (non-MARS group)
Number of subjects: 27
Study: 10903236

Group type: EXPERIMENTAL
Intervention: Diesel exhaust particulates (DEP) at a concentration of 200 microg/m(3) PM(10) for 2 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diesel exhaust particulates (DEP)
Number of subjects: 10
Study: 9052301

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg) plus ketamine (60 mg) administered preoperatively (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural morphine (2 mg) plus ketamine (60 mg) administered postoperatively (Group 2)
Number of subjects: 60
Study: 8110072

Group type: EXPERIMENTAL
Intervention: rh‐EPO treatment for 12 months
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: rh‐EPO treatment for 24 months
Number of subjects: 38
Study: 2874663

Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31023258

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 22
Study: 27839988

Group type: EXPERIMENTAL
Intervention: Western Lyric (WL) singers
Number of subjects: 54

Group type: COMPARATOR
Intervention: Musical Theater (MT) singers
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Long‐term average spectrum analysis
Number of subjects: 54
Study: 25493460

Group type: EXPERIMENTAL
Intervention: eSVS Mesh (treated saphenous vein)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Unsupported saphenous vein (control)
Number of subjects: 90